Executive record

Franklin Berger

Director at Atea Pharmaceuticals, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:franklin-bergerVersion: public-0As of: 2026-09-30

Not yet claimed13 published Claims6 sources
  • Director

Key Claims

Biography

Mr. Berger is a founder of the NEMO Fund at Sectoral Asset Management and previously served as Managing Director and Senior Biotechnology Analyst at J.P. Morgan Securities. He has extensive board experience with multiple public biotechnology companies including ESSA Pharma, Atea Pharmaceuticals and Satellos Bioscience. He holds an M.B.A. from Harvard Business School and degrees from Johns Hopkins University.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Kezar Life Sciences, Inc.

Current

Claims

Executive career

  1. Dates not publishedExecutive title: Founder and Managing Director · Organization not publishedAVIR DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

6 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. AVIR DEF 14A director slate

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 15, 2026

    Supports 4 claims
    • Board role: Board role: Lead Independent Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Audit, Compensation · Claim reviewed: May 15, 2026
    • Executive company: Executive at FMB Research LLC · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Founder and Managing Director · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Apr 29, 2025 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Atea Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026

  3. KZR DEF 14A director slate

    sec filing · Source published: Apr 25, 2025 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Audit, Nominating/Governance · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  4. Open source

    sec proxy · Source published: Apr 25, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Kezar Life Sciences, Inc. · Claim reviewed: May 16, 2026

  5. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Atea Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026

  6. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Kezar Life Sciences, Inc. · Claim reviewed: May 16, 2026